Form 4: LivaNova PLC: Chief Legal Officer Michael Damon Hutchinson Reports Stock Transactions
SEC Form 4
Michael Damon Hutchinson, Chief Legal Officer of LivaNova PLC, reports acquisition and disposal of ordinary shares and grants of restricted stock units, performance stock units, and stock appreciation rights.
Summary
- On March 30, 2024, Michael Damon Hutchinson, the Chief Legal Officer of LivaNova PLC, reported transactions involving the company's stock.
- Hutchinson acquired 1,478 ordinary shares through the vesting of restricted stock units (RSUs) and performance stock units (PSUs).
- He also disposed of 542 shares to cover tax liabilities at a price of $55.94 per share.
- Additionally, Hutchinson was granted 5,809 RSUs, 5,809 PSUs tied to total shareholder return (TSR), 2,904 PSUs tied to free cash flow (FCF), 2,904 PSUs tied to return on invested capital (ROIC), and 12,700 stock appreciation rights (SARs).
- The PSUs vest on March 30, 2027, based on performance metrics over the period from January 1, 2024, to December 31, 2026.
- The RSUs and SARs vest in equal annual installments over four years, starting March 30, 2024, or March 30, 2025.
Sentiment
Score: 6
Explanation: The document is a neutral report of stock transactions. The grants of equity could be seen as a positive sign of confidence in the company's future, but the sale of shares to cover taxes is a neutral event.
Positives
- The granting of RSUs, PSUs, and SARs to the Chief Legal Officer aligns his interests with the long-term performance of the company.
- The vesting of RSUs and PSUs indicates that previous performance milestones were met.
Future Outlook
The document outlines future vesting dates for RSUs, PSUs, and SARs, contingent on continued service and/or the company's performance against specific metrics (TSR, FCF, ROIC) over defined periods.
Industry Context
This filing is a routine disclosure of stock transactions by a company insider, which is common in publicly traded companies. It provides transparency to investors regarding the actions of key personnel.
Comparison to Industry Standards
- Equity compensation practices, such as granting RSUs, PSUs, and SARs, are standard practice among publicly traded companies to incentivize executives.
- Vesting schedules and performance metrics (TSR, FCF, ROIC) are typical components of executive compensation plans, aligning executive interests with shareholder value.
- Comparable companies such as Medtronic, Boston Scientific, and Abbott also utilize similar equity compensation strategies for their executives.
Stakeholder Impact
- The transactions have a minor impact on shareholders as they reflect insider activity related to compensation.
- Employees may be indirectly affected by the performance-based vesting of PSUs, as their efforts contribute to the company's TSR, FCF, and ROIC.
Key Dates
| Date | Description |
|---|---|
| 03/30/2023 | Reporting person was granted RSUs subject to a four-year vesting in equal annual installments, the first vesting having occurred on March 30, 2024. |
| 01/01/2024 | Start date for the three-year performance period for TSR-based PSUs. |
| 03/30/2024 | Date of reported transactions, including acquisition and disposal of shares, and grant of RSUs, PSUs, and SARs. |
| 03/30/2024 | First vesting date for RSUs granted on March 30, 2023. |
| 03/30/2025 | First vesting date for RSUs and SARs granted on March 30, 2024. |
| 12/31/2026 | End date for the three-year performance period for TSR-based PSUs. |
| 03/30/2027 | Vesting date for PSUs based on TSR, FCF, and ROIC performance. |
| 04/02/2024 | Date of signature of the report. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.